Related references
Note: Only part of the references are listed.High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy
Oscar Arrieta et al.
MEDICAL ONCOLOGY (2011)
A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer
Kiyoshi Komuta et al.
CHEMOTHERAPY (2010)
The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Bo Jin et al.
CHEMOTHERAPY (2010)
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial
Noriyasu Usami et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
Christelle Clement-Duchene et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer
Bjorn H. Gronberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gemcitabine and Carboplatin Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Feasibility Study
Young Jin Yuh et al.
Cancer Research and Treatment (2009)
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
Yuval Shaked et al.
CANCER CELL (2008)
Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines
Shinjiro Naga et al.
CHEMOTHERAPY (2008)
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Andrea Ardizzoni et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Y. Ohe et al.
ANNALS OF ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gemcitabine/Carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer
Mana Yoshimura et al.
CLINICAL LUNG CANCER (2006)
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer - West Japan Thoracic Oncology Group (WJTOG) 0104
Nobuyuki Yamamoto et al.
CANCER (2006)
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer
Gregory A. Masters et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: Phase II study of 28-day and 21-day schedules
Coleman K. Obasaju et al.
CLINICAL LUNG CANCER (2005)
Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer
K Hotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
